Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL)

被引:25
|
作者
Monaghan, SA [1 ]
Peterson, LC [1 ]
James, C [1 ]
Marszalek, L [1 ]
Khoong, A [1 ]
Bachta, DJ [1 ]
Karpus, WJ [1 ]
Goolsby, CL [1 ]
机构
[1] Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA
来源
CYTOMETRY PART B-CLINICAL CYTOMETRY | 2003年 / 56B卷 / 01期
关键词
chronic lymphocytic leukemia; immunophenotype; flow cytometry; CD20; FMC7; CD79b;
D O I
10.1002/cyto.b.10049
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: The classic immunophenotype for chronic lymphocytic leukemia (CLL) is CD 19(+), restricted dim surface expression of kappa or lambda light chain, CD5(+), CD23(+), dim CD20(+), negative FMC7, and negative CD79b. However, the necessity of assaying for all 3 pan B-cell markers (CD20, FMC7, and CD79b) by flow cytometry has not been definitively documented for CLL. Methods: Qualitative patterns and semi-quantitative assessment of staining intensity for CD20, FMC7 and CD79b were performed in 70 cases with a current or prior diagnosis of CLL or CLL with increased prolymphocytes leukemia (CLL/PL). The concurrent morphology in 66 of 70 specimens was classified as typical CLL in 53 cases, CLL/PL in 10 cases, and large cell lymphoma in 3 cases. Results: Forty percent of the cases varied from the characteristic immunophenotype by having moderate or bright staining of CD20 (36%), FMC7 (7%), and/or CD79b (18%). Discrepant qualitative staining patterns were found between FMC7 and CD20 (21%), CD20 and CD79b (15%), and CD79b and FMC7 (10%). Semiquantitative measurement of staining intensity showed little correlation between CD79b and CD20 or FMC7. Moderate correlation was seen between CD20 and FMC7. No correlation was observed between morphology and intensity of marker expression. Conclusions: Variable patterns and intensity of staining were seen for FMC7, CD20, and CD79b in this cohort of CLL samples. Dim or negative staining was most consistently seen for FMC7 (93% of specimens). Although FMC7 staining intensity was moderately correlated with CD20, CD79b intensity was poorly correlated with either CD20 or FMC7, and thus, may provide some independent information. Cytometry Part B (Clin. Cytometry) 56B:30-42, 2003. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:30 / 42
页数:13
相关论文
共 50 条
  • [1] Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL).
    Kent, SA
    Peterson, LC
    James, C
    Goolsby, CL
    MODERN PATHOLOGY, 2001, 14 (01) : 168A - 168A
  • [2] Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL).
    Kent, SA
    Peterson, LC
    James, C
    Goolsby, CL
    LABORATORY INVESTIGATION, 2001, 81 (01) : 168A - 168A
  • [3] Leukemic meningitis in B-cell chronic lymphocytic leukemia (CLL).
    Caldera, H
    Raez, L
    Hidron, A
    Henao, A
    Goodman, M
    BLOOD, 1998, 92 (10) : 260B - 260B
  • [4] Mathematical model of B-cell chronic lymphocytic leukemia (CLL)
    Martinis, M
    Vitale, B
    Zlatic, V
    Dobrosevic, B
    Dodig, K
    PERIODICUM BIOLOGORUM, 2005, 107 (04) : 445 - 450
  • [5] Allelotyping in B-cell chronic lymphocytic leukemia (B-CLL)
    Novak, U
    Tobler, A
    Fey, MF
    LEUKEMIA & LYMPHOMA, 2004, 45 (05) : 887 - 896
  • [6] B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia
    Landgren, Ola
    Albitar, Maher
    Ma, Wanlong
    Abbasi, Fatima
    Hayes, Richard B.
    Ghia, Paolo
    Marti, Gerald E.
    Caporaso, Neil E.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (07): : 659 - 667
  • [7] CYTOPLASMIC IMMUNOGLOBULINS IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA (B-CLL)
    COSER, P
    PIANEZZE, G
    BONE MARROW TRANSPLANTATION, 1989, 4 : 151 - 152
  • [8] Prognostic value of translocations in B-CELL chronic lymphocytic leukemia (B-CLL)
    Van den Neste, E.
    Robin, V.
    Maerevoet, M.
    Hagemeijer, A.
    Stul, M.
    Constantini, S.
    Robert, A.
    Ferrant, A.
    Michaux, L.
    ACTA CLINICA BELGICA, 2006, 61 (02) : 99 - 99
  • [9] Surface and cytoplasmic immunoglobulin expression in B-cell chronic lymphocytic leukemia (CLL)
    Lewis, RE
    Cruse, JM
    Pierce, S
    Lam, J
    Tadros, Y
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2005, 79 (02) : 146 - 150
  • [10] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52